Hummingbird bioscience has received US $19 million round B financing, which will be used to enrich the company's product line and rapidly promote the existing antibody therapy

On December 5, 2019, arterial network learned that hummingbird Bioscience, a biomedical company in Singapore, announced the completion of round B financing of USD 19 million This round of financing is jointly led by miraeassetventureinvestment and gntechventurecapital, with existing investors heritas capital and seeds capital, as well as new investors such as Deutsche union capital, miraeassetcapital, davalue giltedge, hbinvestment, wooshinventureinvestment and kiwooominvestment Shinhan capital Hummingbird Bioscience is a biomedical company dedicated to the development of new breakthrough precise antibody therapy for refractory diseases The funds raised in this round will be used to support the company to find new targets, expand the company's product line of the same kind of initiative and the best antibody therapy of the same kind, and support the work of joint research and development projects in the multi-target cooperation agreement signed with Amgen in September this year 。 The company expects to submit clinical trial application in the second half of 2020, and the main products hmbd-001 and hmbd-002 will carry out human clinical trial "With our world-class cancer system biology experts, multi group science and information technology team, hummingbird Bioscience is at the forefront of scientific discovery The support from strategic investors will drive our transformation science and drug development process " Dr piers Ingram, CEO and co-founder of hummingbird Bioscience, said, "our innovation platform can accurately confirm the targets that are difficult to be made into medicine before, and further develop targeted antibody The capability of this platform has been validated by the development of two major candidate drugs, and we are currently collaborating in clinical trials with world-renowned institutions such as Cancer Research UK and cancer prevention Texas We will continue to build product lines across different disease areas to help cancer and other disease patients bring hope for treatment " It is reported that, to date, hummingbird bioscience has obtained more than 60 million US dollars through financing and strategic cooperation Jae Joon Kim, managing director of mirae asset venture investment, said: "hummingbird bioscience has invented a differentiated and rational antibody discovery platform, which can design and generate therapeutic antibodies for difficult and ideal targets We are optimistic about the company's potential to create breakthrough therapies that will benefit the lives of critically ill patients We are pleased to work with hummingbird bioscience's experienced management team and relevant investors " Zhao Guobao, senior vice president of DLC, said: "in recent years, great progress has been made in the biomedical industry, but there are still many potential targets that are difficult to be made into medicines, and there are huge unmet needs Hummingbirdbioscience's rad antibody discovery platform can accurately develop antibody drugs against targets that are difficult to be made into drugs We are optimistic about the value of rad platform in the development of such antibodies and the company's potential management team They have reached extensive and in-depth cooperation with world-class research institutions and large pharmaceutical enterprises in a short period of time " About hummingbirdbioscience hummingbirdbioscience is an innovative biomedical company dedicated to the discovery and development of new breakthrough precise antibody therapy for refractory diseases With its proprietary rational antibody discovery platform and rich experience in system biology, hummingbird bioscience can accurately identify new disease targets, so that it can engineer and generate antibodies to accurately hit these usually difficult targets The company is developing a pipeline of first-class and best candidate drugs across a wide range of indications, including hmbd-001 (anti HER3 antibody) and hmbd-002 (anti Vista antibody) for cancer treatment Hummingbird bioscience has established a strategic partnership with Cancer Research UK and Amgen, and has received product development funding from the Texas Institute for cancer prevention About German Union capital Founded in 2011, Delian capital focuses on technology driven projects in high-end manufacturing, cutting-edge technology, medical and health fields It has invested in ten start-up companies, including yuebo power, China Lithium new materials, yisaitong, Qiming medical, mengke pharmaceutical, Luoshi robot, Huajie Amy, mecamand, covering robotics, intelligent manufacturing, artificial intelligence, big data, enterprise services Medical health and other subdivisions With the mission of "creating value and growth together, and being a long-term reliable partner", DLC practices the core values of "professional focus, openness and truth-seeking, concerted efforts, and sticking to the right and new" Penicillin is the reprinted content of yaozhi.com, and the copyright belongs to the original author The purpose of reprinting is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.